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Circulating biomarkers for detection
of ovarian cancer and predicting cancer
outcomes
I Shapira1,2, M Oswald3, J Lovecchio2,4, H Khalili3, A Menzin2,4, J Whyte2,4, L Dos Santos2,4, S Liang2,5,
T Bhuiya2,5, M Keogh3, C Mason3, K Sultan2,6, D Budman1,2, P K Gregersen2,3 and A T Lee*,2,3
1

Monter Cancer Center, NorthShore LIJ, 450 Lakeville Road, Lake Success, NY 11040, USA; 2Hofstra North Shore-LIJ School of
Medicine, Hempstead, NY, USA; 3The Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030, USA;
4
Department of Gynecology/Oncology, NorthShore LIJ, 300 Community Drive, Manhasset, NY 11030, USA; 5Department of
Pathology, NorthShore LIJ, 5 Ohio Drive, New Hyde Park, NY 11040, USA and 6Department of Gastroenterology, NorthShore LIJ,
350 Community Drive, Manhasset, NY 11030, USA
Background: Securing a diagnosis of ovarian cancer and establishing means to predict outcomes to therapeutics remain
formidable clinical challenges. Early diagnosis is particularly important since survival rates are markedly improved if tumour is
detected early.
Methods: Comprehensive miRNA profiles were generated on presurgical plasma samples from 42 women with confirmed serous
epithelial ovarian cancer, 36 women diagnosed with a benign neoplasm, and 23 comparably age-matched women with no known
pelvic mass.
Results: Twenty-two miRNAs were differentially expressed between healthy controls and the ovarian cancer group (Po0.05), while
a six miRNA profile subset distinguished presurgical plasma from benign and ovarian cancer patients. There were also significant
differences in miRNA profiles in presurgical plasma from women diagnosed with ovarian cancer who had short overall survival
when compared to women with long overall survival (Po0.05).
Conclusion: Our preliminary data support the utility of circulating plasma miRNAs to distinguish women with ovarian cancer from
those with a benign mass and identify women likely to benefit from currently available treatment for serous epithelial ovarian
cancer from those who may not.

Each year, the American Cancer Society estimates over 20 000 new
cases of ovarian cancer will be diagnosed and B15 500 women
died of the disease (Seigel et al, 2012). Although 6% of all cancer
death in women is caused by ovarian cancer, there has been
relatively little improvement in survival rates over the past decade
(Seigel et al, 2012). Five-year survival is critically dependent on
the ovarian cancer stage at diagnosis; if diagnosed and treated while
localised (stages I and II), 5-year survival rates can reach over
90%. However, most ovarian cancer cases are diagnosed as
advanced disease (stages III and IV) where 5-year survival is

o30% (Piver et al, 1992; Berkenblit and Cannistra, 2005; Jemal
et al, 2010).
Disease outcome is significantly higher with early diagnosis,
however, currently there is no non-invasive method to accurately
detect early-stage ovarian cancer (Partridge et al, 2009; Andersen
et al, 2010). This was recently re-confirmed by the US Preventative
Services Task Force that annual screenings with transvaginal
ultrasound and measurement of the cancer antigen, CA-125 serum
levels does not significantly increase survival rates in asymptomatic
women with no genetic risk mutations. In fact, they concluded that

*Correspondence: Dr AT Lee; E-mail: anlee@nshs.edu
Received 5 August 2013; revised 25 November 2013; accepted 27 November 2013;
published online 24 December 2013
& 2014 Cancer Research UK. All rights reserved 0007 – 0920/14

976

www.bjcancer.com | DOI:10.1038/bjc.2013.795

Circulating miRNAs in ovarian cancer

screening for ovarian cancer can lead to unnecessary death from
surgical complications associated with a false positive result
(Moyer, 2012). Other biomarkers such as mesothelin and human
epididymis 4 also have limited diagnostic utility (Andersen et al,
2010; Dutta et al, 2010). There clearly exists an unmet need for a
non-invasive diagnostic tool with sufficient sensitivity and
specificity to positively impact survival rates in ovarian cancer.
MiRNAs are small (19–25 nt), non-coding RNAs that regulate
gene expression post-transcriptionally by binding in the 30
untranslated region (30 UTR) of their specific messenger RNAs
and interfering with translation (Bartel, 2009). The presence and
expression levels of specific tissue miRNAs have been associated
with different stages in ovarian cancer and clinical outcome. Iorio
et al (2007) were the first to compare genome-wide miRNA
expression profiles from both ovarian cancer and normal ovary
tissue. Approximately 30 miRNAs were found to be differentially
expressed between normal and cancerous tissue. Since then several
others have confirmed the dysregulation of miRNAs in ovarian
cancer tissue (Dahiya and Morin, 2010; Creighton et al, 2012).
More recently, it has become apparent that miRNAs circulate in
the peripheral blood in several compartments. They may be found
within exosomes in the plasma or free of cellular material and
bound to proteins such as Argonaut 2 (Arroyo et al, 2011). Thus,
they offer a potential biomarker for a wide range of diseases
(Devaux et al, 2012; Weiland et al, 2012; Rege et al, 2013;
Shen et al, 2013; Zhu et al, 2013). Indeed, there are several reports
of circulating miRNAs associated with ovarian cancer and
correlated with detection, severity of disease, and response to
treatment (Taylor and Gercel-Taylor, 2008; Resnick et al, 2009;
Häusler et al, 2010), although the methods for sample preparation
and miRNA detection vary between studies. In this study, using an
ultracentrifugation method, we focussed on miRNAs that are
circulating freely in the plasma unbound to cellular material as
potential biomarkers for ovarian cancer detection and outcome.
MATERIALS AND METHODS

Samples. We collected peripheral blood samples before treatment
from women being evaluated for a suspicious pelvic mass. We
enrolled 42 women with confirmed serous epithelial ovarian cancer
and 36 women diagnosed with a benign neoplasm. Additional
blood samples were collected from women diagnosed with ovarian
cancer 42 weeks post surgery and 424 months post chemotherapy. Blood samples were also collected from 23 healthy female
volunteers. The characteristics of study subjects are given in
Table 1. The Institutional Review Board of the North Shore–Long
Island Jewish Health System approved these studies.
miRNA extraction and profiling. Whole blood, collected in
EDTA tubes, was centrifuged at 4000 r.p.m. for 10 min at room
temperature within 5 h of venipuncture. Plasma was removed,
aliquoted, and stored at  80 1C. One millilitre of thawed plasma
was ultracentrifuged at 100 000 g for 60 min at 4 1C to remove cell
debris, microvessicles, and exosomes. Total small RNA from the
supernatant was isolated using the mirVana PARIS kit (Ambion,
Grand Island, NY, USA) according to the manufacturer’s
instruction. MiRNA quality was assessed using Agilent’s 2100
bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
Total miRNA profiles were generated using ABI Taqman
OpenArray MicroRNA pools A and B to measure the expression of
754 known miRNAs. Briefly, total small RNA isolated from 1 ml of
purified plasma was divided equally for each sample and used with
TaqMan Megaplex RT primer pools A or B to generate cDNA
which was subsequently amplified using the corresponding
Megaplex PreAmp Primers (pools A or B, respectively) following
the manufacturer’s instructions. Real-time PCR was performed on
www.bjcancer.com | DOI:10.1038/bjc.2013.795
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the Taqman Open Array MicroRNA plates using the Applied
Biosystem Open Array Real-Time PCR system. Data were
processed using the OpenArray Real-Time qPCR Analysis software
and exported for analysis using the Applied Biosystems DataAssist
Software.
Statistical analysis. Data analysis was done with the R programming language. A cutoff for Ct values at 30 was used. MiRNAs with
Ct values higher than 30 were considered as not detected. Data
were normalised using a mean-centering restricted (MCR) strategy
as described by Wylie et al (2011). The MCR method is a
modification of the traditional delta Ct method and uses miRNAs
which are expressed in all samples for data normalisation. The
mean of these fully expressed miRNAs in a given sample is
subtracted from all miRNAs in that sample.
For the comparison of presurgical plasma samples, four miRNAs
(miR-320, -720, -1274b, and U6 RNA) were present in all samples
and were used for normalisation. For the comparison of presurgical
with postsurgical and postchemotherapy samples, 14 miRNAs (miR16, miR-19b, miR-24, mirR-146a, mmu-miR-451, U6 rRNA, miR106a, miR-126, miR-320, miR-191, miR-17, miR-483-5p, miR1274b, and miR-720) were fully expressed and used for data
normalisation. After data were normalised, statistical analysis was
performed via custom scripts based on the R/Bioconductor
package LIMMA (Linear Models for Microarray) (Smyth, 2005).
Comparisons between experimental groups were performed using
a moderated t-test from LIMMA and P-values were adjusted for
multiple testing via the Benjamini–Hochberg method. Fold changes
of each miRNA were calculated by the equation 2  DDCt where the
comparative cycle threshold (DDCt) is defined as the difference
between DCt (cancer/experimental) minus DCt (control) as
previously described (Schmittgen and Livak, 2008). A Benjamini–
Hochberg adjusted P-value of o0.05 was considered as statistically
significant in comparisons between different groups for each miRNA
(Benjamini and Hochberg, 1995). As an additional stringency
requirement, miRNAs were further considered only if they had at
least a 2-fold difference in expression and were present in at least
75% of the samples in each group unless otherwise specified.
Area under the curve (AUC) analysis was performed with
the R/Bioconductor package ROC (Carey and Redestig;
www.bioconductor.org).
RESULTS

Plasma miRNA expression levels in ovarian cancer and cancerfree subjects. Using plasma isolated miRNAs, we generated
comprehensive miRNA expression profiles on presurgical plasma
samples from 42 women with confirmed serous epithelial ovarian
cancer, 36 women diagnosed with a benign neoplasm, and 23
healthy women with no known pelvic mass (Table 1).
We analysed all miRNAs for differential expression between
control plasma and presurgical plasma from confirmed ovarian
cancer patients. Twenty-two of the significant miRNAs met our
criteria of being expressed in at least 75% samples of each group
and demonstrating a fold change of at least 2. These are shown in
Figure 1 and Supplementary Table 1. The majority of miRNAs (19
out of 22) were underexpressed in plasma from cancer patients
compared with controls. In plasma samples from women without a
known pelvic mass (healthy controls) compared with presurgical
plasma samples from women diagnosed with ovarian cancer,
miR-106a, miR-126, miR-146a, miR-150, miR-16, miR-17, miR-19b,
miR-20a, miR-223, miR-24, and miR-92a had at least a 10-fold
elevation in expression, while miR-106b, miR-191, miR-193a-5p,
miR-30b, miR-30a- 5p, miR-30c, miR-320, and miR-328 were
significantly elevated but to a lesser degree (adj. Po0.05;
AUC40.8). Three miRNAs, miR-1274a, miR-625-3p, and
977
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miR-720, were elevated only in cancer samples (adj. Po0.05);
however, they were not useful discriminators between control and
cancer samples (AUCo0.8).
There were only six miRNAs (miR-106b, miR-126, miR-150,
miR-17, miR-20a, and miR-92a, adj. Po0.05) that distinguished
benign presurgical plasma from that of cancer subjects.
In addition to the 22 miRNAs that were significantly differentially
expressed and present in at least 75% of each group, we list
161 miRNAs that were well expressed (|DCt|43) in at least
two subjects of either benign or ovarian cancer subjects
(Supplementary Table 2).
Table 1. Subject summary

Healthy
controls

Benign
mass

Ovarian
cancer

23

36

42

36
18–61

52
34–76

64
31–87

n/a

n/a

Number of subjects

Age at enrollment (years)
Mean
Range
Ovarian cancer stage
IIA

3

IIC

3

IIIA

1

IIIB

12

IIIC

21

IV

2

MiRNA
MiR-106a
MiR-106b
MiR-126
MiR-1274a
MiR-139-5p
MiR-142-3p
MiR-146a
MiR-150
MiR-16
MiR-17
MiR-191
MiR-193a-5p
MiR-19b
MiR-20a
MiR-223
MiR-24
MiR-30a-5p
MiR-30b
MiR-30c
MiR-320
MiR-328
MiR-484
MiR-486
MiR-625-3p
MiR-660
MiR-720
MiR-92a

Control vs benign

Differences in miRNA expression between presurgical benign
samples and normal controls compared with those observed
between controls and ovarian cancer subjects showed differential
expression of 17 overlapping miRNAs (Figure 1; Supplementary
Table 1). There are 10 miRNAs that distinguish plasma of healthy
control subjects from presurgical plasma samples from women
with ovarian cancer or a benign neoplasm. In the comparison of
healthy controls with cancer plasma samples there are five
miRNAs, miR-1274a, miR-30b, miR-30c, miR-625-3p, and miR720 that are differentially expressed. MiR-139-5p, miR-142-3p,
miR-484, miR-486, and miR-660 are higher in healthy controls
when analysed against benign plasma samples.
Presurgical plasma miRNAs associated with long-term outcome
in patients with ovarian cancer. We compared presurgical
plasma miRNA profiles of women who turned out to have ovarian
cancer, and for whom we had outcome data (N ¼ 26). Significant
differences in miRs-720, miR-20a, miR-223, miR-126_3p, and
miR-1290 expression were found in women who had short overall
survival (SOS) (o2 years, N ¼ 19) when compared to women with
long overall survival (LOS) (44 years, N ¼ 7) (Table 2).
MiR-720 and miR-20a were elevated in women who died of
their disease o2 years after diagnosis. Women who survived 44
years after diagnosis have elevated levels of miR-223, miR-126-3p,
and miR-1290 in their presurgical plasma (Table 2). However, after
correction for multiple testing, only the level of miR-1290 was
significantly different between the two groups (adj. P-valueo0.05,
AUC of 0.87). Age and clinical stage at diagnosis were comparable
for both groups analysed (Table 3).
The expression levels of miR-1290 detected in all samples
included in this study are shown in Figure 2 and Table 3.

Control vs cancer

NS
NS
NS

Benign vs cancer
NS

NS
NS
NS
NS
NS
NS
NS
NS

NS
NS

NS
NS
NS
NS
NS

NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS

Fold change
(–2.0) – (–4.0)
2.0–4.0
4.1–6.0
6.1–8.0
8.1–10
10.1–12.0
12.1–14.0
14.1–16.0
16.1–18.0
18.1–20.0
20.1–22.0
22.1–24.0
24.1–26.0
26.1–28.0
28.1–30.0
30.1–32.0

Figure 1. Comparison of plasma miRNA levels between subject groups. Comparisons of plasma miRNA levels from subjects diagnosed with
ovarian cancer, a benign mass, or healthy controls. Only miRNAs that had at least a 2-fold change in expression present in at least 75% of each group
were used in the analysis. Po0.05 (cancer subjects n ¼ 42, benign subjects n ¼ 36, healthy controls n ¼ 23). Abbreviation: NS ¼ not significant.
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Table 2. Comparison of miRNAs in presurgical plasma of LOS vs SOS
subjects

ID

P-value

Adj. P-value

Fold change

AUC

miR-720

0.002

0.079

 4.57

0.13

miR-20a

0.03

0.3

 2.63

0.15

miR-223

0.03

0.3

miR-126-3p
miR-1290

4.474

0.73

0.016

0.24

4.818

0.74

0

0.004

14.566

0.87

Abbreviations: AUC ¼ area under the curve; LOS ¼ long overall survival; SOS ¼ short overall
survival.

MiR-1290 was present in all of the samples from LOS subjects
(7 out of 7) tested but was detected in only 12 out of 19 SOS, 15 out
of 16 UND, 13 out of 23 control, and 12 out of 36 benign subjects.
In this data set, miR-1290 was calculated to have a sensitivity of
63.3% and 100% specificity for long-term survival in subjects with
ovarian cancer (e.g., considering only people with ovarian cancer)
with a PPV and a PNV of 100% and 75%, respectively. In addition
to the differentially expressed miRNAs that were found in at least
50% of the samples, we list 71 miRNAs that were found to be
significantly expressed (|DCT|X3) in at least 2 individuals of either
the LOS or SOS subject group (Supplementary Table 3).
Changes of miRNA expression in plasma of ovarian cancer
patients after surgical treatment and chemotherapy. Five LOS
subjects had presurgical and postchemotherapy plasma samples
available for analysis. There were seven miRNAs that were
differentially expressed between matched presurgical and postchemotherapy samples. These changes are summarised in Figure 3,
Supplementary Table 4, and Supplementary Figure 1. MiR-1274a,
miR-1274b, and miR-1290 displayed consistent decreases in plasma
levels after treatment, whereas miR-19b, -25, -195, and -16 were
more highly expressed in postchemotherapy samples when compared
with their respective presurgical plasma sample (adj. Po0.05).
The comparison of presurgical with immediate postsurgical
plasma samples, measured before chemotherapy, did not show any
significant differences in miRNA expression in paired analyses
from the same subjects (n ¼ 9; data not shown).
DISCUSSION

To address several unanswered questions regarding the utility of
circulating miRNAs as biomarkers in ovarian cancer, we analysed
blood samples from women diagnosed with ovarian cancer, a
benign neoplasm, or healthy control samples. A number of
considerations were taken into account before analysing miRNAs
from plasma. For example, the use of circulating miRNAs as
biomarkers of cancer have come under increased scrutiny, due to
lack of standardised miRNA isolation methods and the possibility
of contamination of RBC, lymphoid and myeloid-derived miRNAs.
Pritchard et al (2012) reported the potential for confounding
factors related to miRNA contamination from lysed cells in
previously reported studies including ovarian cancer. Therefore, to
minimise the contribution of miRNAs from lysed PBMCs, RBCs,
platelets, and other cellular debris, plasma was isolated within 5 h
of blood draw. Second, after an initial low speed centrifugation, the
plasma was removed and ultracentrifuged leaving only protein
bound miRNA in the supernatant. It has been suggested that the
majority of disease-related miRNAs found in circulation are vesicle
independent originating from the lysis of affected cells
(Turchinovich et al, 2011). We confirmed the absence of cellular
www.bjcancer.com | DOI:10.1038/bjc.2013.795

Table 3. Ovarian cancer subject summary and miR-1290 levels

Subject
ID

Age Dx

Cancer
stage

DCt

Survival
(years)

UND
1

53

IA

5.9

41 but o4

2

51

IIA

5

41 but o4

3

79

IIIB

 3.2

4

59

IIIB

 3.4

41 but o4

5

51

IIIB

1.3

41 but o4

41 but o4

6

63

IIIB

0.7

41 but o4

7

67

IIIB

3.8

41 but o4

8

63

IIIB

5.4

41 but o4

9

57

IIIC

 2.8

41 but o4

10

74

IIIC

 1.7

41 but o4

11

50

IIIC

3.4

41 but o4

12

58

IIIC

5.2

41 but o4

13

78

IIIC

4.5

41 but o4

14

50

IIIC

6.8

41 but o4

15

86

IV

5.9

4 1 but o4

16

60

IV

ND

41 but o4

LOS
17

57

IA

3.2

44

18

51

IIC

2.6

44

19

31

IIC

4.4

44

20

70

IIIB

 0.6

44

21

65

IIIB

2.4

44

22

62

IIIC

 1.8

44

23

66

IIIC

3.7

44

SOS
24

57

IIC

ND

o2

25

55

IIIA

ND

o2

26

69

IIIB

3.4

o2

27

75

IIIB

5.2

o2

28

60

IIIB

7

o2

29

69

IIIB

ND

o2

30

58

IIIC

1.8

o2

31

66

IIIC

2.5

o2

32

54

IIIC

4.7

o2

33

77

IIIC

7.4

o2

34

83

IIIC

7.4

o2

35

79

IIIC

6.5

o2

36

85

IIIC

6.7

o2

37

65

IIIC

8.7

o2

38

76

IIIC

8.8

o2

39

75

IIIC

ND

o2

40

54

IIIC

ND

o2

41

87

IIIC

ND

o2

42

72

IIIC

ND

o2

Abbreviations: LOS ¼ long overall survival; ND ¼ not detected; SOS ¼ short overall survival;
UND ¼ undeclared survival outcome.
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debris including microvessicles and exosomes in the supernatant
by electron microscopy (data not shown). The stable presence
of microvessicle and exosome-free miRNAs in circulation is
MiR-1290

6
4
2

–ΔCt

0
–2
–4
–6
–8
–10
–12

UND

LOS

SOS

BGN

CNTRL

Group

Figure 2. Level of miR-1290 in subject groups. Individual levels of
miR-1290 detected in plasma samples from subjects with ovarian
cancer, a benign mass, or healthy controls. Expressed as  (DCt),
see also Supplementary Table 2. Abbreviations: BGN ¼ benign mass
(n ¼ 32); CNTRL ¼ healthy control (n ¼ 23); LOS ¼ long overall survival
44 years (n ¼ 7); SOS ¼ short overall survival o2 years (n ¼ 19);
UND ¼ undeclared survival (n ¼ 16).

dependent upon being bound to Ago 2 to protect them from
degradation (Arroyo et al, 2011).
Previous studies have identified circulating miRNAs in serum
(Resnick et al, 2009, Chung et al, 2013), exosomes (Taylor and
Gercel-Taylor, 2008), and whole blood (Häusler et al, 2010) from
ovarian cancer subjects. Resnick et al (2009) identified eight
miRNAs in the serum of 28 ovarian cancer patients. Mir-21,-92, -93,
-126, and -29a were elevated in presurgical serum of cancer
patients while miR-155, -127, and -99b were lower in cancer
patients compared with healthy controls. More recently, Cheung
et al (2013) found miR-132, -26a, -145, and let7b to be
underexpressed in serum of ovarian cancer patients. In a study
by Taylor and Gercel-Taylor (2008), it was found that exosomes
isolated from serum of ovarian cancer expressed higher levels of
miR-21, -141, -200a, 200b, 200c, 203, 205, and -214 when
compared to patients with benign ovarian disease. Häusler et al
(2010) measured miRNA levels in 24 patients with relapsed
ovarian cancer. In comparison with controls, they found four
miRNAs that remained significantly expressed after adjustment for
multiple testing; miR-30c1-3p, 342-3p, 181a-3p, and 450b-5p.
A comparison of circulating miRNAs identified to distinguish
control and/or benign from cancer subjects from previous studies
including our own, failed to identify common miRNAs expressed
in the same subject group. Interestingly, Resnick et al (2009) found

MiR-25
0

Subject 21
Subject 18

–1

Subject 21

Subject 17

–2

Subject 18

Subject 23

–ΔCt

–ΔCt

MiR-1290
1
0
–1
–2
–3
–4
–5
–6

Subject 19

Subject 17

–3

Subject 23

–4

Subject 19

–5
Pre

Post

Pre

MiR-16
0

Subject 18

–2

2

Subject 21

Subject 17

–4

Subject 18

1

Subject 23

0

Subject 19

–ΔCt

Subject 21

3

Subject 23
–8

–2

–10
Pre

2
1
0
–1
–2
–3
–4
–5
–6

Subject 17

–6

–1
Post

Subject 19
Pre

MiR-1274a
Subject 21
Subject 18
Subject 17
Subject 23
Subject 19

Pre

Post
MiR-1274b

Post

–ΔCt

–ΔCt

4

–ΔCt

Post
MiR-195

7
6
5
4
3
2
1
0

Subject 21
Subject 18
Subject 17
Subject 23
Subject 19
Pre

Post

–ΔCt

MiR-19b
3
2.5
2
1.5
1
0.5
0
–0.5
–1
–1.5

Subject 21
Subject 18
Subject 17
Subject 23
Subject 19

Pre

Post

Figure 3. Presurgical vs postchemotherapy plasma miRNAs in LOS subjects. MiRNAs demonstrating significant differences between presurgical
and postchemotherapy plasma samples of women with long overall survival (n ¼ 5). Expressed as  (DCt), see also Supplementary Figure 1 and
Supplementary Table 4.
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miR-126 to be elevated in serum from cancer patients while we
found more robust levels of miR-126 in plasma samples from
healthy control and benign mass subjects. This discrepancy among
ours and previous studies may be attributable to the source of
miRNAs (whole blood, plasma, serum, or exosomes) from primary
ovarian cancer or relapse patients, and/or the platform (qPCR or
microarray based) used for analysis.
While we recognise that some highly expressed miRNAs
relevant to ovarian cancer may go undetected due to degradation,
tissue sequestration, or microvessicle/exosome containment, those
that we have identified may be seminal to detection and outcome
of the disease. To the best of our knowledge, this is the first serous
epithelial ovarian cancer study to specifically focus on circulating,
protein bound miRNAs in plasma, free of cellular debris,
microvessicles, and exosomes.
Initially, we set out to determine whether specific circulating
miRNAs could be used to detect the presence of ovarian cancer in
subjects being evaluated for a pelvic mass. We assessed the
expression patterns of 754 miRNAs in presurgical plasma samples
from 42 women with confirmed serous epithelial ovarian cancer
compared with 36 plasma samples collected from women who
turned out to have a benign pelvic mass at surgery. We also
compared both of these groups with age-matched healthy subjects
without evidence of pelvic pathology. Interestingly, both cancerous
and benign neoplasms were generally associated with lower levels
of a group of 22 circulating miRNAs, as shown in Figure 1. A much
smaller subset of six miRNAs were significantly different between
groups of women with cancer vs a benign neoplasm suggesting that
benign neoplasms are associated with a circulating miRNA profile
with some similarity to ovarian cancer. Of these, miR-106b, miR-150,
and miR-126 have been previously reported to have decreased
expression in ovarian cancer tissue compared with non-cancerous
ovarian tissue (Iorio et al, 2007; Dahiya et al, 2008; Zhang et al,
2008). There does not seem to be an obvious overlap in gene
targets/pathways of these three miRNAs to explain their lowered
expression in ovarian cancer. We also found significantly elevated
expression of miR-17, miR-20a, and miR-92a of the miR-17-92
cluster in presurgical plasma from women with a benign neoplasm
compared to women with ovarian cancer. The role and the
function of these miRNAs in cancer are difficult to identify since
their function is both cell type and context specific (Olive et al,
2010; Concepcion et al, 2012).
In 2011, the TCGA (Cancer Genome Atlas Research Network,
2011) published and made available genetic, epigenetic, and
expression data on 489 high-grade serous ovarian cancer tissue
samples. We downloaded and analysed level 3 miRNA microarray
expression data of women with ovarian cancer who had not been
previously treated for their disease (i.e., adjuvant, chemotherapy).
The six miRNAs (miR-106b, miR-126, miR-150, miR-17, miR-20a,
and miR-92a) we found to be elevated in presurgical plasma from
benign compared with cancer patients were well expressed in
ovarian cancer tissue from this data set, however, without
comparable miRNA expression data from samples with benign
ovarian disease the significance of miRNA expression of miRNAs
in ovarian cancer tissue could not be determined.
To take into account the possibility that highly expressed
miRNAs in a small number of subjects could also distinguish
benign from ovarian cancer subjects, we relaxed our miRNA
inclusion criteria to include miRNAs that had a |DCt| of 43 and
were present in at least two subjects of either the benign or the
ovarian cancer group. One hundred and sixty-one samples met this
modified criteria, of these 21 were present in presurgical plasma
from subjects with a benign mass and 22 were present in
presurgical plasma from women subsequently diagnoses with
ovarian cancer (Supplementary Table 2). The relevance of these
uniquely expressed miRNAs in either benign or ovarian cancer
presurgical plasma will need to be evaluated in a larger data set.
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We also examined the utility of presurgical circulating plasma
miRNA in predicting outcome of those subjects who turned out to
have ovarian cancer at operation. Using follow-up data available on
26 ovarian cancer subjects in our study, we compared presurgical
plasma miRNA profiles of women who died within 2 years of
diagnosis (but survived at least 6 months post surgery) from those
who survived 4 years or more. Although 5-year survival is
standard, we chose to include subjects with at least 4-year survival
for our LOS group to include enough subjects for meaningful
analysis. We found distinct differences between these two groups.
There were five miRNAs (miR-720, miR-20a, miR-223, miR-126-3p,
and miR-1290) that were differentially expressed between LOS and
SOS subjects, however, only miR-1290 remained significant after
multiple testing adjustments (adj. P ¼ 0.004) (Table 2).
There were additional 71 miRNAs that were significantly
present (|DCt|X3) but were detectable in o50% of the LOS or
SOS group (Supplementary Table 3). Nineteen of these miRNAs
were only found in presurgical plasma samples from SOS while
four were present only in LOS subjects. Due to the small number of
subjects further analysis could not be performed to determine
significance. Using our criteria for LOS and SOS we analysed
TCGA miRNA microarray level 3 data for the corresponding tissue
miRNA associated with outcome. None of the miRNAs available
for analysis were significant.
The expression of miR-1290 may directly influence outcome in
women with ovarian cancer and its expression is independent of
age and cancer stage at diagnosis. One highly scored potential gene
target of miR-1290 is epithelial membrane protein 2 (EMP2)
(Supplementary Table 5). EMP2 is a tetraspan protein that
facilitates transmembrane activity of specific integrins and can
act as an oncogene in a number of cancers (Freije et al, 2004; Fu
et al, 2010; Habeeb et al, 2010) and its elevated expression has been
associated with poor outcome in patients with endometrial cancer
(Wadehra et al, 2006). EMP2 is also expressed in ovarian cancer
although unlike with endometrial cancer, the level of expression
was not associated with patient survival. In vitro and in vivo
treatment of ovarian cancer cells with an engineered bivalent
antibody against EMP2 inhibited cell growth and resulted in cell
death (Fu et al, 2010). It is conceivable that elevated expression of
miR-1290 observed in the LOS subjects led to decreased expression
of EMP2 and consequently resulted/contributed to their long-term
cancer-free status. Finally, a comparison of presurgical and
postsurgical plasma samples from matched individuals did not
show any significant differences. This is most likely explained by
the timing of ascertainment which was B2 weeks post surgery and
may have been too soon to detect relevant changes. However,
analysis of presurgical and postchemotherapy plasma (cured)
samples from LOS subjects showed a dramatic change in miRNA
profiles. Although based on a relatively small number of matched
presurgical and postchemotherapy sample pairs (5), these miRNAs
(miR-1274a, miR-1274b, miR-1290, miR-19b, miR-25, miR-195,
and miR-16) maintained their significance even after multiple
testing corrections (adj. Po0.05). Interestingly, miR-1290 whose
elevated expression was predictive of survival in presurgical plasma
is decreased in long overall survivors (44 years) of ovarian cancer
suggesting that it may be induced/regulated in the presence of
ovarian cancer. Although suppressed in presurgical plasma miR-19b,
miR-25, miR-195, and miR-16 are elevated in the LOS subjects. In
particular, there is a 10-fold elevation of miR-16 in LOS
postchemotherapy plasma samples when compared with presurgical plasma samples. A recent paper by Pouliot et al (2012) showed
that transfection of a miR-16 mimic into cisplatin-resistant cells
resulted in a 5-fold increase in cisplatin sensitivity although the
mechanism is undefined. Cisplatin is a common chemotherapy
used to treat ovarian cancer among others and one could envision
that chemosensitivity maintained by elevated levels of miR-16
during the chemotherapy contributes to a favourable outcome in
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our LOS subjects. To confirm effects of miR-1290 and miR-16 to
support long-term cancer-free status in ovarian cancer, confirmation and validation in a larger multi-site cohort will be needed.
Given the general nature of miRNAs associated with cancers, it is
highly likely these miRNAs have a pivotal role in cell proliferation
and/or metastasis but their specific role in affecting ovarian cancer
outcome, whether directly or indirectly, remains to be determined.
Further studies will be needed to confirm the extent that
circulating levels of miRNAs are reflective of disease status.
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Häusler SF, Keller A, Chandran PA, Ziegler K, Zipp K, Heuer S,
Krockenberger M, Engel JB, Hönig A, Scheffler M, Dietl J, Wischhusen J
(2010) Whole blood-derived miRNA profiles as potential new tools for
ovarian cancer screening. Br J Cancer 103: 693–700.
Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C,
Volinia S, Liu CG, Alder H, Calin GA, Ménard S, Croce CM (2007)
MicroRNA signatures in human ovarian cancer. Cancer Res 67: 8699–8707.
Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60:
277–300.
Moyer VA (2012) Screening for ovarian cancer: U.S. Preventive Services Task
Force reaffirmation recommendation statement. Ann Intern Med 157:
900–904.
Olive V, Jiang I, He L (2010) mir-17-92, a cluster of miRNAs in the midst
of the cancer network. Int J Biochem Cell Biol 42: 1348–1354.
Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, Kessel B,
Johnson CC, Weissfeld JL, Isaacs C, Andriole GL, Ogden S, Ragard LR,
Buys SS. PLCO Project Team (2009) Results from four rounds of
ovarian cancer screening in a randomized trial. Obstet Gynecol (2009)
113: 775–782.
Piver MS, Malfetano J, Baker TR, Hempling RE (1992) Five-year survival for
stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatinbased chemotherapy. Gynecol Oncol 46: 357–360.
Pouliot LM, Chen YC, Bai J, Guha R, Martin SE, Gottesman MM, Hall MD
(2012) Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by
miR-155 and the miR-15 family. Cancer Res 72: 5945–5955.
Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM,
Tait JF, Tewari M (2012) Blood cell origin of circulating microRNAs:
a cautionary note for cancer biomarker studies. Cancer Prev Res 5: 492–497.
Rege SD, Geetha T, Pondugula SR, Zizza CA, Wernette CM, Ramesh Babu J
(2013) Noncoding RNAs in neurodegenerative diseases. ISRN Neurol 30:
375852.
Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE (2009)
The detection of differentially expressed microRNAs from the serum of
ovarian cancer patients using a novel real-time PCR platform. Gynecol
Oncol 112: 55–59.
Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the
comparative C(T) method. Nat Protoc 3: 1101–1108.
Shen J, Stass SA, Jiang F (2013) MicroRNAs as potential biomarkers in human
solid tumors. Cancer Lett 329: 125–136.
Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin
62: 10–29.
Smyth G (2005) Linear models for microarray data. In Bioinformatics and
Computational Biology Solutions Using R and Bioconductor, Gentleman R,
Carey V, Dudoit S, Irizarry R, Huber W (eds) pp 397–420. Springer:
New York.
Taylor DD, Gercel-Taylor C (2008) MicroRNA signatures of tumor-derived
exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110:
13–21.
Turchinovich A, Weiz L, Langheinz A, Burwinkel B (2011) Characterization
of extracellular circulating microRNA. Nucleic Acids Res 39: 7223–7233.
Wadehra M, Natarajan S, Seligson DB, Williams CJ, Hummer AJ, Hedvat C,
Braun J, Soslow RA (2006) Expression of epithelial membrane protein-2 is
associated with endometrial adenocarcinoma of unfavorable outcome.
Cancer 107: 90–98.
Weiland M, Gao XH, Zhou L, Mi QS (2012) Small RNAs have a large impact:
circulating microRNAs as biomarkers for human diseases. RNA Biol 9:
850–859.
Wylie D, Shelton J, Choudhary A, Adai AT (2011) A novel mean-centering
method for normalizing microRNA expression from high-throughput
RT-qPCR data. BMC Res Notes 4: 555.

www.bjcancer.com | DOI:10.1038/bjc.2013.795

Circulating miRNAs in ovarian cancer
Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG,
Giannakakis A, Alexiou P, Hasegawa K, Johnstone CN, Megraw MS,
Adams S, Lassus H, Huang J, Kaur S, Liang S, Sethupathy P,
Leminen A, Simossis VA, Sandaltzopoulos R, Naomoto Y, Katsaros D,
Gimotty PA, DeMichele A, Huang Q, Bützow R, Rustgi AK,
Weber BL, Birrer MJ, Hatzigeorgiou AG, Croce CM, Coukos G (2008)
Genomic and epigenetic alterations deregulate microRNA expression in
human epithelial ovarian cancer. Proc Natl Acad Sci USA 105: 7004–7009.

BRITISH JOURNAL OF CANCER
Zhu S, Pan W, Qian Y (2013) MicroRNA in immunity and autoimmunity.
J Mol Med (Berl) 91: 1039–1050.

This work is licensed under the Creative Commons
Attribution-NonCommercial-Share Alike 3.0 Unported
License. To view a copy of this license, visit http://creativecommons.
org/licenses/by-nc-sa/3.0/

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)

www.bjcancer.com | DOI:10.1038/bjc.2013.795

983

